- Home
- CPRX vs TARS Comparison
CPRX vs TARS Comparison
Compare CPRX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- TARS
- Stock Information
- Founded
- CPRX 2002
- TARS 2016
- Country
- CPRX United States
- TARS United States
- Employees
- CPRX N/A
- TARS 323
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- TARS Medicinal Chemicals and Botanical Products
- Sector
- CPRX Health Care
- TARS Health Care
- Exchange
- CPRX Nasdaq
- TARS Nasdaq
- Market Cap
- CPRX 2.6B
- TARS 2.8B
- IPO Year
- CPRX 2006
- TARS 2020
- Fundamental
- Price
- CPRX $21.29
- TARS $66.87
- Analyst Decision
- CPRX Strong Buy
- TARS Strong Buy
- Analyst Count
- CPRX 5
- TARS 7
- Target Price
- CPRX $33.20
- TARS $69.43
- AVG Volume (30 Days)
- CPRX 1.4M
- TARS 636.9K
- Earning Date
- CPRX 11-05-2025
- TARS 11-12-2025
- Dividend Yield
- CPRX N/A
- TARS N/A
- EPS Growth
- CPRX 183.96
- TARS N/A
- EPS
- CPRX 1.65
- TARS N/A
- Revenue
- CPRX $558,499,000.00
- TARS $295,521,000.00
- Revenue This Year
- CPRX $16.59
- TARS $137.28
- Revenue Next Year
- CPRX $8.80
- TARS $42.84
- P/E Ratio
- CPRX $12.72
- TARS N/A
- Revenue Growth
- CPRX 28.55
- TARS 254.45
- 52 Week Low
- CPRX $19.05
- TARS $38.48
- 52 Week High
- CPRX $26.58
- TARS $76.81
- Technical
- Relative Strength Index (RSI)
- CPRX 57.67
- TARS 53.26
- Support Level
- CPRX $20.66
- TARS $65.30
- Resistance Level
- CPRX $21.55
- TARS $74.83
- Average True Range (ATR)
- CPRX 0.57
- TARS 2.82
- MACD
- CPRX 0.05
- TARS -1.01
- Stochastic Oscillator
- CPRX 84.24
- TARS 13.64
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.